TAPI-1

Overview

TAPI-1 is a broad-spectrum MMP inhibitor and NF-κB p65 inhibitor that targets ADAM17/TACE , ADAM10 and other proteins. TAPI-1 reduces the proteolytic cleavage of membrane-bound TNF-α , decreases TNF-α levels, inhibits NF-κB pathway activation, and downregulates profibrotic markers. TAPI-1 reduces the proportion of proinflammatory immune cells, alleviates cardiac and airway fibrosis, and improves cardiac function after myocardial infarction. Meanwhile, TAPI-1 inhibits the viability, migration and invasion of esophageal squamous cell carcinoma cells, enhances the chemosensitivity of Cisplatin ( HY-17394 ), induces apoptosis , and shows low toxicity to normal esophageal epithelial cells. TAPI-1 can be widely used in studies related to myocardial infarction-induced heart failure, severe traumatic tracheal stenosis, esophageal squamous cell carcinoma and other conditions.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > MMP | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > TNF Receptor

Product Information

• Catalog No.: HY-16657
• CAS No.: 163847-77-6
• Molecular Formula: C26H37N5O5
• Molecular Weight: 499.60
• Purity: 99.36%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (4.16 mM); Clear solution
• Availability: In-stock

Source

Original product source